Cell therapy (Stem-cell derived) · Immune activation · developed by Mesoblast
Remestemcel-L is an allogeneic cell therapy made of adult human mesenchymal stromal cells harvested from bone marrow of donors and expanded ex vivo. Its immunomodulatory activity is thought to involve inhibition of T cell activation and pro-inflammatory cytokine secretion. It is studied in graft versus host disease, Crohn's disease, chronic obstructive pulmonary disease, and acute respiratory distress syndrome.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 11, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04371393 | Phase 3 | Mesenchymal Stromal Cells | Terminated | MESO |
| NCT00482092 | Phase 3 | Crohn's Disease | Completed | MESO |
| NCT00683722 | Phase 2 | Pulmonary Disease, Chronic Obstructive | Completed | MESO |
| NCT00294112 | Phase 2 | Crohn's Disease | Completed | MESO |
| NCT00284986 | Phase 2 | Graft Versus Host Disease | Completed | MESO |
| NCT00136903 | Phase 2 | Graft Vs Host Disease | Completed | MESO |
| NCT01510431 | N/A | Crohn's Disease | No longer available | MESO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Respiratory Distress SyndromeChronic BronchitisCOVIDCrohn's DiseaseGraft Versus Host DiseaseGraft Vs Host DiseaseMesenchymal Stromal CellsPulmonary Disease, Chronic ObstructivePulmonary EmphysemaRemestemcel-L
Updated Oct 18, 2026. Something wrong or missing? Report it on the MESO page.
See MESO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MESO catalysts and pipeline →